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A majority of early colorectal cancers (CRCs) with submucosal invasion undergo
surgical operation, despite a very low incidence of lymph node metastasis. Our
study aimed to identify microRNAs (miRNAs) specifically responsible for lymph
node metastasis in submucosal CRCs. MicroRNA microarray analysis revealed that
miR-100 and miR-125b expression levels were significantly lower in CRC tissues
with lymph node metastases than in those without metastases. These results
were validated by quantitative real-time PCR in a larger set of clinical samples.
The transfection of a miR-100 or miR-125b inhibitor into colon cancer HCT116
cells significantly increased cell invasion, migration, and MMP activity. Con-
versely, overexpression of miR-100 or miR-125b mimics significantly attenuated
all these activities but did not affect cell growth. To identify target mRNAs, we
undertook a gene expression array analysis of miR-100-silenced HCT116 cells as
well as negative control cells. The Ingenuity Pathway Analysis, TargetScan soft-
ware analyses, and subsequent verification of mRNA expression by real-time PCR
identified mammalian target of rapamycin (mTOR) and insulin-like growth factor
1 receptor (IGF1R) as direct, and Fas and X-linked inhibitor-of-apoptosis protein
(XIAP) as indirect candidate targets for miR-100 involved in lymph node metasta-
sis. Knockdown of each gene by siRNA significantly reduced the invasiveness of
HCT116 cells. These data clearly show that downregulation of miR-100 and miR-
125b is closely associated with lymph node metastasis in submucosal CRC
through enhancement of invasion, motility, and MMP activity. In particular, miR-
100 may promote metastasis by upregulating mTOR, IGF1R, Fas, and XIAP as tar-
gets. Thus, miR-100 and miR-125b may be novel biomarkers for lymph node
metastasis of early CRCs with submucosal invasion.
R ecent advances in endoscopic technology enable us to cor-rectly diagnose relatively early CRCs. At the same time,
with the development of endoscopic therapies, including endo-
scopic mucosal resection and endoscopic submucosal dissec-
tion, we are now able to completely remove en bloc CRCs
with limited invasion to the superficial submucosal layer.(1)
However, it has been reported that approximately 10% of
CRCs with submucosal invasion metastasize to lymph nodes.(2)
In the absence of lymph node metastasis, CRCs with submu-
cosal invasion could be cured by endoscopic treatment alone.
However, surgical operation with lymph node resection is
commonly carried out to treat CRCs with submucosal invasion,
as we have no reliable diagnostic method to detect small
lymph node metastasis. In fact, the Japanese and European
guidelines recommend surgical resection when the CRC infil-
trates into the deep submucosal layer (>1 mm).(3,4) The US
guideline recommends surgical resection for CRC with submu-
cosal invasion, regardless of the depth of submucosal
invasion.(5) However, lymph node metastases are rarely
detected in resected tissues from surgical operations. Consider-
ing these clinical circumstances, the development of novel
biomarkers specifically related to lymph node metastasis is
very important for the treatment of CRCs with submucosal
invasion.
MicroRNAs are a class of small non-coding RNA molecules
of 20–25 nt that regulate gene expression through transcrip-
tional repression and mRNA degradation.(6–10) Accumulating
evidence has shown that miRNAs are involved in carcinogene-
sis, metastasis, and invasion in various types of cancers.(11,12)
Moreover, the recent development of miRNA microarray assay
has made possible to evaluate the expression of >3000 miR-
NAs simultaneously.(13) Using this method, several studies
detected miRNAs responsible for metastasis of human CRCs.
Li et al.(14) showed that decreased miR-99b expression in
metastatic lesions of the liver from CRCs promoted cell inva-
sion through enhancement of mTOR expression. Yuan et al.(15)
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reported that miR-145 expression was significantly higher in
CRC with lymph node metastasis than in CRC without lymph
node metastasis, and showed that forced expression of miR-
145 enhanced invasion and metastasis of HCT-8 cells through
stabilization of heat shock protein-27 mRNA. Conversely, it
was reported that miR-145 expression was decreased in lung
cancer with lymph node metastasis.(16,17) However, these
reports mainly focused on advanced CRCs (stage III and IV),
and early CRCs with submucosal invasion were not investi-
gated.
In our study, by analyzing miRNA expression profiles in
submucosal invasive CRCs with and without lymph node
metastasis, we identified miR-100 and miR-125b as possible
miRNAs useful for risk assessment of lymph node metastasis
in CRC. We also identified their target genes, which facilitate
invasion and migration of CRC cells.
Materials and Methods
Tissue specimens. We enrolled six patients with submucosal
invasive CRC with lymph node metastasis and 10 patients with
submucosal invasive CRC without lymph node metastasis.
Baseline characteristics of the patients are shown in Table S1.
Specimens were obtained by endoscopic mucosal resection or
surgical removal, fixed in 10% formalin, and embedded in
paraffin. Written informed consent was obtained from all
patients according to the guidelines approved by the Ethics
Committee of Tokushima University Hospital (approval no.
1318-1).
Cell lines. Human CRC cell lines (HT29, SW480, RKO, and
HCT116) were purchased from ATCC (Manassas, VA, USA).
COLO 205 was purchased from RIKEN Cell Bank (Kobe,
Japan). HT29 and HCT116 cells were cultured in McCoy’s 5A
medium containing 10% FBS, SW480 cells were cultured in
Leibovitz’s L-15 medium containing 10% FBS, RKO cells
were cultured in the Minimum Essential Medium Eagle con-
taining 10% FBS, and COLO 205 cells were cultured in
RPMI-1640 medium containing 10% FBS.
MicroRNA microarray. After macrodissection of 20-lm CRC
tissue slices, total RNA was extracted using a miRNeasy FFPE
Kit (Qiagen, Hilden, Germany). A human miRNA microarray
(version 3, based on Sanger miRbase release 12.0; Agilent
Technologies, Palo Alto, CA, USA) was used for measuring
global miRNA expression in CRC samples. Total RNA was
labeled with cyanine 3-cytidine bisphosphate by T4 ligase and
hybridized to SurePrint G3 human miRNA microarray release
16.0 using miRNA complete labeling reagent and hybridization
kit (Agilent Technologies). Subsequently, each sample was
scanned by a DNA Microarray Scanner (G2505C; Agilent
Technologies), and fluorescence signal was extracted using
Feature Extraction Software (version 10.7.3.1). Raw intensity
miRNA data were analyzed by GeneSpring GX 12 (Agilent
Technologies).
Gene expression and pathway analyses. Total RNA was
extracted from HCT116 cells using an RNeasy Mini Kit (Qia-
gen). The quality of the purified RNA was assessed, and gene
expression was measured using a whole human genome
microarray (SurePrint G3 Human GE 8x 60K; Agilent Tech-
nologies) as described previously.(18) Microarray data were
analyzed by GeneSpring GX 12. The functional pathways
related to the set of differentially expressed genes were
assessed by IPA (http://www.ingenuity.com). TargetScan
(http://www.targetscan.org/) was also used to predict the target
of miRNA.
TaqMan real-time RT-PCR. Total RNA was extracted from
human CRC tissues as described above. Mature miRNA levels
were measured using TaqMan MicroRNA Assays (Applied
Biosystems, Foster City, CA, USA). RNU48 snRNA was used
as an internal quantity control for normalization. The following
TaqMan microRNA assays reagents (Applied Biosystems)
were used: hsa-miR-100 (000437), hsa-miR-125a-5p
(002198), hsa-miR-125b (000449), hsa-miR-155 (002623), hsa-
miR-30a-5p (000417), hsa-miR-342-3p (002260), and RNU48
(001006).
Total RNA was also extracted from HCT116 cells using an
RNeasy Mini Kit. Amounts of mRNAs were measured by
TaqMan qPCR and normalized by 18S ribosomal RNA (18S
rRNA) using the following TaqMan primer sets (Applied
Biosystems): mTOR (Hs00234522_m1), IGF1R (Hs00609566_
m1), Fas (Hs00181225_m1), XIAP (Hs00745222_s1), and 18S
rRNA (Hs03928985_g1). The relative expression levels of
each sample were measured by the 2DDCT method.
Overexpression or knockdown experiments. A specific inhibi-
tor for miR-100 or miR-125b (mirVana miRNA Inhibitor; Life
Technologies, Karlsruhe, Germany) was used for knockdown
experiments, and a miR-100 or miR-125b mimic (mirVana
miRNA mimic; Life Technologies) was used for overexpres-
sion experiments. HCT116 cells (14.4 9 105) were plated in
60-mm diameter dishes and transfected with one of the two
inhibitors or mimics at a final concentration of 30 nM using
the Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA,
USA) in Opti-MEM medium (Gibco Life Technologies,
Gaithersburg, MD, USA). A miRNA inhibitor negative control
(mirVana miRNA inhibitor, negative control #1; Life Tech-
nologies) or miRNA mimic negative control (mirVana miRNA
mimic, negative control #1; Life Technologies) was transfected
as the respective negative control. HCT116 cells were trans-
fected with 30 nM siRNA targeting mTOR (Silencer Select
s604; Ambion, Austin, TX, USA) (sense, GGAGCCUUGU
UGAUCCUUATT; antisense, UAAGGAUCAACAAGGCU
CCAT), IGF1R (Silencer Select s7211; Ambion) (sense,
GCAUGGUAGCCGAAGAUUUTT; antisense, AAAUCUUC
GGCUACCAUGCAA), Fas (Silencer Select s1506; Ambion)
(sense, GGAAGACUGUUACUACAGUTT; antisense, ACU-
GUAGUAACAGUCUUCCTC), and XIAP (Silencer Select
s1454; Ambion) (sense, GGAUAUACUCAGUUAACAATT;
antisense, UUGUUAACUGAGUAUAUCCAT) using Lipofec-
tamine RNAiMAX. A scramble siRNA (Silencer Negative
Control #1, AM4611; Ambion) was used as a control siRNA.
Cell invasion assay. After transfection with the miRNA inhi-
bitor, miRNA mimic, or siRNA, the cells were starved in
serum-free media for 16 h. Subsequently, the in vitro invasion
assay was carried out using the CultreCoat 96-well BME Cell
Invasion Assay Kit (Trevigen, Gaithersburg, MD, USA) as pre-
viously described.(19) Experiments were carried out six times.
Wound healing assay. Cells (2.0 9 106 cells) were trans-
fected with miRNA inhibitor or miRNA mimic for 24 h in
six-well plates. The confluent cell layer was scratched using a
200-lL pipette tip, gently washed with PBS, and incubated in
the culture medium containing 10% FBS. Wound healing was
imaged every 30 min for 48 h using BioStation CT (Nikon,
Tokyo, Japan). Wound healing ability was determined by mea-
suring the migration distance in five points per sample at 16 h
after the scratch.
Matrix metalloproteinase activity and cell proliferation assays.
Cells were transfected with miRNA inhibitors or mimics in
60-mm diameter dishes for 24 h. After washing, they were
incubated with fresh medium for 24 h, and the conditioned
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medium was collected. Matrix metalloproteinase activities
(MMP-1, 2, 7, 8, 9, 13, 14, 15, and 16) were measured using
the Sensolyte 390 generic MMP activity kit (AnaSpec, Fre-
mont, CA, USA) as previously described.(20) For the prolifera-
tion assay, after transfection with a miRNA inhibitor or
mimic, cells (3.0 9 103) were plated in a 96-well plate and
incubated in McCoy’s 5A medium with 10% FBS. Viable cells
were counted at 6, 24, 48, 72, 96, and 120 h using a Cell
Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan).
Statistical analysis. The unpaired t-test was used to assess
difference in miRNA array expression between human CRC
tissues with and without lymph node metastasis. The Mann–
Whitney U-test was used to assess difference in real-time PCR
expression between human CRC tissues with and without
lymph node metastasis. Dunnett’s test was used to assess dif-
ference in invasion, proliferation, and MMP activity between
control cells and cells transfected with miRNA inhibitors,
mimics, or siRNAs. In the network analysis using the IPA sys-
tem, the probability of a relationship between each biological
function and the identified genes was calculated by the Fish-
er’s exact test. The level of significance was set at a P-value
of 0.05.
Results
Differentially expressed miRNAs in metastatic CRC. To find
miRNAs involved in CRC lymph node metastasis, we first
undertook miRNA microarray analysis of submucosal invasive
CRC tissues and compared miRNA expression profiles
between three non-metastatic and three metastatic CRCs (cases
1–3 and 7–9, respectively; Table S1). The expression levels of
miR-125a-5q, miR-125b, miR-155, miR-342-3p, miR-100, and
miR-30a-5p were significantly lower in the metastatic CRCs
than in the non-metastatic CRCs (Table 1), and the average
fold changes were 1.74, 2.73, 2.47, 2.94, 2.80, and
2.81, respectively.
Validation of miRNA expression by qPCR. To validate the dif-
ferential expression of the six miRNAs, their levels were mea-
sured by qPCR in 10 non-metastatic and six metastatic CRC
tissues (Table S1). The amounts of miR-100 and miR-125b in
the metastatic CRCs were significantly lower than in the non-
metastatic CRCs (P = 0.0092 and 0.0067, respectively;
Table 2). However, we could not detect significant difference
in the expression levels of miR-125a-5q, miR-155, miR342-3p,
or miR-30a-5p. Thus, we identified miR-100 and miR-125b as
putative miRNAs involved in lymph node metastasis of CRCs
with submucosal invasion.
Effects of miRNA inhibitors or mimics on cell invasion. To
detect possible roles of miR-100 and miR-125b in malignant
phenotypes of colon cancer cells, we first analyzed the
expression of miR-100 and miR-125b in colon cancer cell
lines (HT29, SW480, HCT116, RKO, and COLO205) by
qPCR. Among the cell lines examined, HCT116 cells
expressed moderate amounts of miR-100 and miR-125b that
are the most suitable for both knockdown and overexpres-
sion experiments (Fig. S1). To test whether altered expres-
sion of miR-100 or miR-125b could modify the invasiveness
of colon cancer cells, we transfected inhibitors or mimics
specific for the two miRNAs in HCT116 cells, and assessed
the invasive ability. The invasion of HCT116 cells trans-
fected with a miR-100 or miR-125b inhibitors was signifi-
cantly higher than that of cells transfected with a miRNA
inhibitor negative control (Fig. 1a). In contrast, transfection
with a miR-100 or miR-125b mimic significantly reduced
cell invasion compared with a negative control mimic
(Fig. 1b). We also carried out similar experiments using
another CRC cell line, RKO, and obtained similar results on
cell invasion (Fig. S2). These results suggest that miR-100
and miR-125b suppress CRC cell invasion. In addition, when
both miR-100 and miR-125b inhibitors were simultaneously
transfected into HCT116 cells, their invasiveness was slightly
more enhanced compared to that of transfectant with each
inhibitor alone, despite no significant difference. Likewise,
cotransfection of miR-100 and miR-125b mimics into
HCT116 cells slightly attenuated their invasiveness compared
to transfection with each mimic alone, despite no significant
difference (Fig. S3).
Effects of miRNA inhibitors or mimics on migration, cell
growth, and MMP activities. Next, we examined the effects of
miRNA inhibitors or mimics on HCT116 cell migration. As
shown in Figure 2, both miR-100 and miR-125b inhibitors
increased HCT116 cell migration and significantly accelerated
wound healing compared with control cells. In contrast, the
miR-100 and miR-125b mimics significantly impaired wound
healing (Fig. 2c,d). When RKO cells were transfected with
miR-100 and miR-125b inhibitors or mimics, similar results
were obtained on cell migration (Fig. S4). Moreover, we
assessed growth promoting activities of miR-100 and miR-
125b using the WST-8 assay. As shown in Figure 3, however,
silencing and overexpression of miR-100 or miR-125b did not
influence HCT116 cell growth. Likewise, silencing of miR-
100 or miR-125b did not influence RKO cell growth
(Fig. S5). Thus, the reduction of miR-100 or miR125b levels
significantly augmented cell invasion and migration without
altering their growth rate. We also examined the effects of
Table 1. MicroRNA (miRNA) levels decreased in metastatic colorectal
cancer (CRC) compared to non-metastic CRC
miRNA
Change relative to
non-metastatic CRC
P-value†
miRBase
accession no.
hsa-miR-125a-5p 1.77 0.020 MIMAT0000443
hsa-miR-125b 2.73 0.026 MIMAT0000423
hsa-miR-155 2.47 0.033 MIMAT0000646
hsa-miR-342-3p 2.94 0.035 MIMAT0000753
hsa-miR-100 2.80 0.039 MIMAT0000098
hsa-miR-30a-5p 2.81 0.042 MIMAT0000087
†Corresponding P-values were calculated using unpaired t-test.
Table 2. MicroRNA (miRNA) expression in non-metastatic and
metastatic colorectal cancers validated by Taqman PCR
miRNA
Mean miRNA expression (relative
to RNU48)
P-value‡
Non-metastatic
tumor (n = 10)†
Metastatic
tumor (n = 6)†
hsa-miR-100 1.358  0.414 0.092  0.039 0.0092
hsa-miR-125b 4.631  1.618 0.284  0.131 0.0067
hsa-miR-125a-5p 0.484  0.204 0.162  0.115 0.1585
hsa-miR-155 0.761  0.318 0.682  0.438 0.4477
hsa-miR-342-3p 0.473  0.132 0.451  0.409 0.1289
hsa-miR-30a-5p 2.351  0.921 0.851  0.568 0.2328
†Values are miRNA levels (mean  SEM) normalized by RNU48 levels.
‡Corresponding P-values were calculated using the Mann–Whitney U-
test.
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inhibitors or mimics on MMP activities. Silencing of miR-100
significantly increased MMP activities, and miR-100 mimic
overexpression significantly reduced those activities (Fig. 2e,
f). Instead, neither miR-125 inhibitor nor mimic affected
MMP activities (Fig. 2e,f). Thus, miR-100 is likely to be
involved in the regulation of both migration and MMP
activities, suggesting that miR-100, rather than miR-125b,
may be a possible candidate responsible for the regulation of
CRC invasion.
Putative targets. To identify miR-100 target mRNAs
involved in cell invasion, we first compared the gene expres-
sion profile in miR-100-silenced HCT116 cells with HCT116
Fig. 1. Effects of microRNA (miRNA) inhibitors or
mimics on cell invasion. (a) HCT116 cells were
transfected with miR-100 inhibitor, miR-125b
inhibitor, or miRNA inhibitor negative control
(Inhibitor-NC), and an invasion assay was carried
out. (b) HCT116 cells were transfected with miR-100
mimic, miR-125b mimic, or miRNA mimic negative
control (Mimic-NC), and an invasion assay was
undertaken. All experiments were carried out six
times. *P < 0.05; **P < 0.01.
Fig. 2. Effects of microRNA (miRNA) inhibitors or mimics on migration and MMP activities. (a, b) HCT116 cells were transfected with miR-100
inhibitor, miR-125b inhibitor, or miRNA inhibitor negative control (Inhibitor-NC), and a wound healing assay was undertaken. (c, d) HCT116 cells
were transfected with miR-100 mimic, miR-125b mimic, or miRNA mimic negative control (Mimic-NC), and a wound healing assay was under-
taken. (e) HCT116 cells were transfected with miR-100 inhibitor, miR-125b inhibitor, or miRNA inhibitor negative control (Inhibitor-NC), and an
MMP activity assay was undertaken. (f) HCT116 cells were transfected with miR-100 mimic, miR-125b mimic, or miRNA mimic negative control
(Mimic-NC), and an MMP activity assay was undertaken. **P < 0.01 versus controls. RFU, relative fluorescence units.
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cells transfected with the miRNA inhibitor negative control.
Silencing of miR-100 upregulated and downregulated 54 and
57 genes >1.5-fold, respectively. The 111 differentially
expressed genes were subjected to the IPA search. The top
five “molecular and cellular functions” related to the differen-
tially expressed genes are listed in Table 3. We also surveyed
putative miR-100 target mRNAs. The IPA and TargetScan
analyses picked two miR-100 target genes (mTOR and
IGF1R) from the differentially expressed genes, which partic-
ipate in both “metastasis” and “invasion of cells” (Table 3).
The TargetScan analysis indicated that miR-100 directly
interacts with mTOR and IGF1R mRNAs (Fig. S6). The IPA
also picked 10 indirect miR-100 target genes (FAS, XIAP,
PAPPA, TFF3, SPARC, SLC9A1, PDLIM3, FUT7, NCOA1,
and DKK3) among the differentially expressed genes, whose
functions are related to “metastasis” and/or “invasion of
cells” (Table 3). Of these, FAS, XIAP, and PAPPA mRNA
levels changed >2-fold after miRNA silencing compared with
control cells. Based on these findings, we selected the five
genes mTOR, IGF1R, Fas, XIAP, and PAPPA as candidate
targets of miR-100.
Identification of miR-100 targets responsible for cell inva-
sion. To examine whether miR-100 actually controlled the
expression of the five genes mTOR, IGF1R, Fas, XIAP, and
PAPPA, we measured changes in expression levels of these
mRNAs by qPCR after silencing miR-100 (HCT116/inhibitor)
or overexpressing miR-100 (HCT116/mimic). The miR-100
inhibitor significantly increased mTOR, Fas, XIAP, and IGF1R
mRNA levels (Fig. 4a), whereas the miR-100 mimic signifi-
cantly decreased them (Fig. 4b), compared with the respective
controls. However, PAPPA mRNA could not be detected in
HCT116 cells transfected with negative controls, inhibitors, or
mimics. Similar results were obtained when miR-100 and
miR-125b inhibitors or mimics were transfected into RKO
cells (Fig. S7).
Finally, to test whether mTOR, Fas, XIAP, and IGF1R are
involved in the regulation of cell invasion, we examined the
effect of siRNA targeting each gene. As shown in Fig-
ure 4(c), transfection of the specific siRNA targeting each
gene significantly suppressed invasion. In the analysis of cell
growth for these transfectants, there were no significant
differences between the transfectants and control cells
(Fig. S8). Thus, it is evident that mTOR, Fas, XIAP, and
IGF1R are indeed involved in the regulation of cell
invasion.
Discussion
We report here that miR-100 and miR125b are downregulated
in early CRCs with lymph node metastasis with submucosal
invasion. The expression levels of miR-100 and miR125b were
inversely correlated with invasion and migration capabilities of
CRC cell lines (HCT116 and RKO) but not with growth-pro-
moting abilities. The levels of miR-100, but not miR-125b,
were inversely correlated with MMP activities in HCT116
cells. Finally, we identified mTOR, Fas, XIAP, and IGF1R as
miR-100 targets, probably involved in the accelerated invasive-
ness of CRCs with submucosal invasion. In fact, immunohisto-
chemical analysis on the 16 CRC tissues (10 non-metastatic
and six metastatic CRCs) revealed that quantitative immunos-
taining scores for all four these genes in submucosal CRC with
lymph node metastasis were significantly higher than in those
without lymph node metastasis (Fig. S9). Knockdown of these
proteins significantly suppressed the invasion of HCT116 cells.
Thus, the present study suggests miR-100 as a useful biomar-
ker for diagnosis and treatment of early CRCs with submu-
cosal invasion.
Yuan et al.(15) reported the increased expression of miR-145
in CRC with lymph node metastasis. They also showed that
miR-100 and miR-125b levels in CRC tissues with lymph node
metastasis are significantly higher than in CRCs without lymph
node metastasis, thus contradicting our results. In our miRNA
microarray analysis, miR-145 levels were decreased in submu-
cosal invasive CRCs with lymph node metastasis compared
with CRCs without lymph node metastasis. They examined
miR-145 expression in CRCs with and without lymph node
metastasis from stage I to stage IV (mainly stage III). In con-
trast, we enrolled patients with early stage CRCs with limited
invasion to the submucosal layer. The size of the tumors
examined in our study ranged from 10 to 20 mm in diameter,
and there was no significant difference in the size of the lesion
in cases with and without lymph node metastasis. Therefore,
our samples may be suitable for analysis of miRNAs partici-
pating in lymph node metastasis in the early stages of CRC.
Consistent with our findings, it has been reported that miR-100
and miR-125b levels are significantly lower in metastatic pros-
tate cancer and osteosarcoma, respectively.(21,22)
Of the four genes identified as miR100 targets (mTOR, Fas,
XIAP, and IGF1R), mTOR, a downstream member of the
phosphoinositide 3-kinase/Akt/mTOR pathway, is known as a
central regulator of cell growth and differentiation. Recently,
Fig. 3. Effects of microRNA (miRNA) inhibitors or
mimics on cell growth. (a) HCT116 cells were
transfected with miR-100 inhibitor, miR-125b
inhibitor, or miRNA inhibitor negative control
(Inhibitor-NC), and a cell proliferation assay was
undertaken. (b) HCT116 cells were transfected with
miR-100 mimic, miR-125b mimic, or miRNA mimic
negative control (Mimic-NC), and a cell
proliferation assay was undertaken. OD, optical
density.
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mTOR has been reported to play a pivotal role in metastasis
of cancer cells through enhanced motility and invasiveness, E-
cadherin downregulation, and MMP-2 upregulation.(23,24) Thus,
it is highly plausible that downregulated miR-100 promotes
lymph node metastasis through mTOR. The IGF1 receptor
plays a critical role in carcinogenesis. Recently, Li et al.(25)
reported that IGF1/IGF1R signaling induces tumor-associated
lymphangiogenesis and contributes to lymphatic metastasis in
advanced CRCs. Our results suggest that IGF1R may play an
important role in lymph node metastasis, even in early CRCs
with submucosal invasion. Fas/FasL signaling is well known to
be a crucial mediator of cell apoptosis. However, Zheng
et al.(26) indicated that low-dose Fas stimulation induced
epithelial–mesenchymal transition to promote tumor motility
and metastasis in gastrointestinal cancer in vivo and in vitro.
Therefore, it is possible that persistent weak Fas signals may
stimulate lymph node metastasis in early CRCs with
submucosal invasion. An inhibitor of apoptosis, XIAP, is over-
expressed in various types of cancers.(27) Shi et al.(28) reported
that XIAP was closely associated with metastatic capability,
invasiveness, and resistance to apoptosis in hepatocellular car-
cinoma cells. Upregulated XIAP may be involved in lymph
node metastasis in submucosal invasive CRCs. Thus, all four
miR-100 target genes (mTOR, IGF1R, Fas, and XIAP) may
promote lymph node metastasis in submucosal invasive CRCs.
Eventually, in order to identify miR-125b target mRNAs, we
also compared the gene expression profile in miR-125b-
silenced HCT116 cells and control cells. We found 16 differ-
entially expressed genes (>1.5-fold). The IPA and TargetScan
analyses of these genes picked one gene, XIAP. The TargetS-
can analysis indicated that miR-125b may interact with XIAP.
The IPA did not pick any other indirect target genes among
these genes whose functions are related to “metastasis” and/or
“invasion” of cells. Thus, downregulation of miR-125b may
Table 3. Ingenuity pathway analysis and TargetScan analyses of 111 differentially expressed genes in HCT116 cells treated with a microRNA-
100 (miR-100) inhibitor
Functions Related genes P-values†
Direct target of miR-100 related with “invasion
of cells” and “metastasis”
MTOR↑, IGF1R↑
Indirect target of miR-100 related with
“invasion of cells” and/or “metastasis”
Fas↑, XIAP↑, PAPPA↓, TFF3↑, PDLIM3↓, FUT7↓, NCOA1↓, SPARC↑, SLC9A1↑, DKK3↓
Top 5 molecular and cellular functions
1. Cell death and survival Fas↑, NR5A2↑, TFF3↑, IL21↑, TRAF1↓, NR4A3↓, SH3BP2↓, XIAP↑, SLC4A1↓, SFTPC↑,
TSC1↓, SPARC↑, NCOA1↓, SLC8A1↓, HSPB6↓, SLC9A1↑, CSHL1↓, GPR37L1↑, DKK3↓,
ORAI1↑, CHAT↑, PAX4↑
4.14E-05
2. Cellular compromise Fas↑, IL21↑, SLC9A1↑, SLC4A1↓, SPARC↑, SH3BP2↓, XIAP↑, ORAI1↑, TSC1↓ 2.83E-04
3. Cellular function and maintenance SLC8A1↓, SLC9A1↑, IL21↑, SH3BP2↓, FCN1↑, Fas↑, SLC4A1↓, SLC9A1↑, GORASP1↓,
CHAT↑, SEC16A↓, ORAI1↑, TSC1↓, CDKL5↑, MAP6↓
4.23E-04
4. Molecular transport SLC8A1↓, SLC9A1↑, SLC26A11↓, SLC4A1↓, Fas↑, NR5A2↑, PITPNC1↓, CHRNB4↑,
CLCC1↑, KCNQ5↑, TSC1↓, PGAP1↓, CSHL1↓, MTR↑, C1QTNF5↓, CHAT↑, FOLR3↓,
NR4A3↓, SEC13↓, KCNQ5↑
4.23E-04
5. Small molecule biochemistry SLC8A1↓, SLC9A1↑, Fas↑, MTR↑, OBP2B↓, NR5A2↑, PITPNC1↓, NCOA1↓, SLC4A1↓,
PGAP1↓, CSHL1↓, POFUT1↓
4.23E-04
↑, upregulated gene; ↓, downregulated gene. †Calculated by Fisher’s exact test.
Fig. 4. Identification of microRNA (miR)-100
targets responsible for cell invasion. (a, b) Changes
in the expression levels of five genes mTOR, IGF1R,
Fas, XIAP, and PAPPA were measured by
quantitative PCR after silencing (a, HCT116/
inhibitor) or after overexpressing miR-100 (b,
HCT116/mimic). (c) HCT116 cells were transfected
with a random siRNA or the siRNA targeting mTOR,
Fas, XIAP, or IGF1R, and an invasion assay was
carried out. *P < 0.05; **P < 0.01 versus controls.
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promote lymph node metastasis by upregulating XIAP and/or
other unknown target genes. A more detailed analysis of miR-
125b targets should be investigated in the future.
One limitation of our study is the relatively small number of
clinical samples examined. The prevalence of lymph node
metastasis is low (only approximately 10%) in CRC with sub-
mucosal invasion. Therefore, it is difficult to obtain sufficient
numbers of CRC samples with lymph node metastasis.(2) It
would be necessary to investigate the expression of miR-100,
miR-125b expression, and target genes in a large number of
CRC specimens with submucosal invasion with and without
lymph node metastasis as a multicenter study.
In conclusion, our study shows that downregulation of miR-
100 and miR-125b is closely associated with lymph node
metastasis in early CRC with intrasubmucosal invasion through
enhancement of invasion, motility, and MMP activity. In par-
ticular, downregulation of miR-100 may promote lymph node
metastasis by upregulating mTOR and IGF1R as direct targets,
and Fas and XIAP as indirect targets. Thus, miR-100 and
miR-125b may be novel biomarkers for lymph node metastasis
of early CRCs with submucosal invasion.
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Supporting Information
Additional Supporting Information may be found online in the supporting information tab for this article:
Fig. S1. MicroRNA (miR)-100 and miR-125b expression in various colorectal cancer cell lines. Relative miR-100 (a) or miR-125b (b) expression
levels in HT-29, COLO205, SW480, HCT116, and RKO cells were measured by TaqMan real-time PCR. RNU48 was used as an internal control.
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Fig. S2. Effects of microRNA (miRNA) inhibitors or mimics on cell invasion. (a) RKO cells were transfected with miR-100 inhibitor, miR-125b
inhibitor, or miRNA inhibitor negative control (Inhibitor-NC), and an invasion assay was undertaken. (b) RKO cells were transfected with miR-
100 mimic, miR-125b mimic, or miRNA mimic negative control (Mimic-NC), and an invasion assay was undertaken. All experiments were car-
ried out six times. *P < 0.05; **P < 0.01.
Fig. S3. Combined effects of microRNA (miR)-100 and miR-125b inhibitors or mimics on cell invasion. (a) HCT116 cells were transfected with
miR-100 inhibitor, miR-125b inhibitor, miR-100 inhibitor + miR-125b inhibitor or miRNA inhibitor negative control (Inhibitor-NC), and an inva-
sion assay was undertaken. (b) HCT116 cells were transfected with miR-100 mimic, miR-125b mimic, miR-100 mimic + miR-125b mimic or
miRNA mimic negative control (Mimic-NC), and an invasion assay was undertaken. *P < 0.05; **P < 0.01.
Fig. S4. Effects of microRNA (miRNA) inhibitors or mimics on migration. (a, b) RKO cells were transfected with miR-100 inhibitor, miR-125b
inhibitor, or miRNA inhibitor negative control (Inhibitor-NC), and a wound healing assay was carried out. (c, d) RKO cells were transfected with
miR-100 mimic, miR-125b mimic, or miRNA mimic negative control (Mimic-NC), and a wound healing assay was carried out. **P < 0.01.
Fig. S5. Effects of microRNA (miRNA) inhibitors on cell growth. RKO cells were transfected with miR-100 inhibitor, miR-125b inhibitor, or
miRNA inhibitor negative control (Inhibitor-NC), and a cell proliferation assay was carried out. OD, optical density.
Fig. S6. Predicted consequential pairing of microRNA (miR)-100 and the target regions of mammalian target of rapamycin (mTOR) and insulin-
like growth factor 1 receptor (IGF1R). The TargetScan analysis revealed that miR-100 directly interacts with mTOR and IGF1R mRNAs; miR-
100 possesses complementary matches to sequences within the 30-UTRs of mTOR (position 295–301). Likewise, miR-100 represents complemen-
tary matches to sequences within the 30-UTRs of IGF1R (position 5602–5609).
Fig. S7. Identification of microRNA (miR)-100 targets responsible for cell invasion. (a, b) Changes in the expression levels of the five genes
mTOR, IGF1R, Fas, XIAP, and PAPPA were measured by quantitative PCR after silencing (a, RKO/inhibitor) or after overexpressing miR-100 (b,
RKO/mimic). *P < 0.05; **P < 0.01 versus controls.
Fig. S8. Effects of siRNA for mammalian target of rapamycin (mTOR), Fas, X-linked inhibitor-of-apoptosis protein (XIAP), or insulin-like growth
factor 1 receptor (IGF1R) on cell growth. (a) HCT116 cells were transfected with random siRNA or siRNA for mTOR, Fas, XIAP or IGF1R, and
a cell proliferation assay was carried out. No statistically significant differences in cell growth were observed between the transfectants of the
siRNA for mTOR, Fas, XIAP, or IGF1R, or of random siRNA. OD, optical density. (b) Relative mRNA levels for mTOR, Fas, XIAP, and IGF1R
were measured by quantitative PCR at 48 h to validate knockdown efficiency of these genes. Representative data at 48 h are shown. **P < 0.01
versus controls.
Fig. S9. Immunohistochemical staining for mammalian target of rapamycin (mTOR), insulin-like growth factor 1 receptor (IGF1R), Fas, and X-
linked inhibitor-of-apoptosis protein (XIAP) in colorectal cancer (CRC) tissue. Immunohistochemical staining was carried out using the labeled
streptavidin–biotin method with rabbit anti-human mTOR antibody (ab2732), rabbit anti-human IGF-1R antibody (bs-0227R), rabbit anti-human
Fas antibody (119-16559), or rabbit anti-human XIAP antibody (ab21278). (a, b) mTOR, (c, d) IGF1R, (e, f) Fas, and (g, h) XIAP in CRC tissues
without lymph node (LN) metastasis (9100) and with LN metastasis (9100). Scores for percentage of positive cells were assigned as follows: 0,
≤10% of cells positive; 1, 11–25% of cells positive; 2, 26–50% of cells positive; 3, 51–75% of cells positive; and 4, >75% of cells positive.
Scores for staining intensity were assigned as follows: 0, no staining; 1, light brown; 2, brown; and 3, dark brown. Overall scores were obtained
by multiplying the percentage score by the intensity score. The Mann–Whitney U-test was used to assess difference in immunohistochemical score
between human CRC tissues with and without lymph node metastasis. IQR, interquartile range.
Table S1. Baseline characteristics of the patients who participated in this study. We undertook microRNA (miRNA) microarray analysis of sub-
mucosal invasive colorectal cancer (CRC) tissues and compared miRNA expression profiles between three non-metastatic (cases 1–3) and three
metastatic (cases 7–9) CRCs. To validate the differential expression of the six miRNAs, their levels were measured by quantitative PCR in 10
non-metastatic and six metastatic CRC tissues (cases 1–16).
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